ALGN vs JAZZ

ALGN's Piotroski F-Score of 4/9 indicates weak financial health, signaling potential operational inefficiencies despite stable profitability. The absence of an Altman Z-Score raises concern about default risk, though the company's extremely low debt/equity ratio (0.03) and strong liquidity support financial stability. The stock trades near its intrinsic value of $166.68 but at a premium to the Graham Number ($84.93), reflecting high growth expectations. Analysts maintain a 'buy' consensus with a target price of $201.57, suggesting upside, though recent insider selling and inconsistent earnings surprises temper enthusiasm.

JAZZ presents a stark contradiction between fundamental health and market valuation, anchored by a weak Piotroski F-Score of 2/9. While the company exhibits an extremely attractive valuation with a Forward P/E of 7.74 and a PEG ratio of 0.63, its internal financial health is deteriorating, evidenced by negative profit margins and ROE. Despite a massive 1-year price surge of 90.3%, bearish insider sentiment and a low technical trend score suggest a potential peak or internal instability. The stock currently functions as a high-risk value play where analyst optimism clashes with poor deterministic health metrics.